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Array-CGH Reveals Recurrent Genomic Changes in
Merkel Cell Carcinoma Including Amplification
of L-Myc
Kelly G. Paulson1,2,15, Bianca D. Lemos1,2,15 , Bin Feng3, Natalia Jaimes4, Pablo F. Pen˜as5, Xiaohui Bi6,
Elizabeth Maher7, Lisa Cohen8,9, J. Helen Leonard10, Scott R. Granter11,12, Lynda Chin13,14 and Paul Nghiem1,2
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with poorly characterized genetics.
We performed high resolution comparative genomic hybridization on 25 MCC specimens using a high-density
oligonucleotide microarray. Tumors frequently carried extra copies of chromosomes 1, 3q, 5p, and 6 and lost
chromosomes 3p, 4, 5q, 7, 10, and 13. MCC tumors with less genomic aberration were associated with improved
survival (P¼ 0.04). Tumors from 13 of 22 MCC patients had detectable Merkel cell polyomavirus DNA, and these
tumors had fewer genomic deletions. Three regions of genomic alteration were of particular interest: a deletion
of 5q12-21 occurred in 26% of tumors, a deletion of 13q14-21 was recurrent in 26% of tumors and contains the
well-characterized tumor suppressor RB1, and a previously unreported focal amplification at 1p34 was present in
39% of tumors and centers on L-Myc (MYCL1). L-Myc is related to the c-Myc proto-oncogene, has transforming
activity, and is amplified in the closely related small cell lung cancer. Normal skin showed no L-Myc expression,
whereas 4/4 MCC specimens tested expressed L-Myc RNA in relative proportion to the DNA copy number gain.
These findings suggest several genes that may contribute to MCC pathogenesis, most notably L-Myc.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a neuroendocrine cancer of
the skin. It is believed to arise from the sensory Merkel cells
normally found in the lower epidermis and hair follicles
(Haeberle et al., 2004; Boulais and Misery, 2007). Clinically,
MCC typically presents as a rapidly growing, painless, red
nodule on sun-exposed skin and carries a poor prognosis
(Heath et al., 2008). Indeed, MCC is lethal in 33% of cases
(Hodgson, 2005) and thus has a worse prognosis than that of
melanoma (American Cancer Society, 2006). Improved
diagnostic techniques and an aging population have con-
tributed to a rapid rise in the reported incidence; currently
1,500 new cases of MCC are diagnosed annually in the
United States (Lemos and Nghiem, 2007).
The key oncogenic events in MCC are not well under-
stood. Recently, a search for unique cDNA sequences present
in MCC identified a previously unreported polyomavirus that
was present in 8 of 10 tumor samples (Feng et al., 2008).
Although existing data suggest that this virus is neither
necessary nor sufficient for developing MCC, it is an open
question as to whether the virus contributes to carcinogenesis
in a subset of cases.
Forays into several major cancer pathways including p53
(Van Gele et al., 2000), Wnt (Liu et al., 2007), c-Kit (Swick
et al., 2007), BRAF, and other MAP kinase pathway members
(Houben et al., 2006) have revealed little involvement of
these canonical cancer pathways in the pathogenesis of
MCC. The generally null findings of these directed investiga-
tions highlight the need for an unbiased approach to identify
candidate oncogenic pathways for further exploration.
Comparative genomic hybridization (CGH) is a technique
used to map regions of copy number alteration in a cancer
genome. CGH compares DNA derived from cancer cells to
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normal diploid DNA to detect copy number imbalance in
cancer cells. Classical chromosome CGH relies on light
microscopy of metaphase spreads and resolution is thus
limited. Several studies have used chromosome CGH in MCC
(Harle et al., 1996; Van Gele et al., 1998, 2002; Popp et al.,
2002; Larramendy et al., 2004) but did not have sufficient
resolution to delineate specific candidate oncogenes or tumor
suppressors. Modern array-CGH technology on oligonucleo-
tide microarrays improves resolution up to a thousand fold
and can define copy number alterations in regions as small as
a single gene (Brennan et al., 2004). Array-CGH has been
employed successfully to profile genetic aberrations and
identify cancer-relevant genes in many malignancies such as
lung and pancreatic cancer (Aguirre et al., 2004; Tonon et al.,
2005).
We performed array-CGH on 25 MCC tumor samples
using a DNA-microarray imprinted with 440,000 oligonu-
cleotides that spanned the genome with a distance of only
24 kb between probes in gene rich regions. This greatly
improved resolution has allowed identification of several
focal regions of aberration containing candidate genes for
further investigation in MCC pathogenesis.
RESULTS
Patient and tumor characteristics
We studied 28 MCC tumor specimens from 25 patients with
MCC. Our samples were a mixture of formalin-fixed paraffin-
embedded (FFPE) tumors and flash-frozen tumors. Data were
excluded from three FFPE specimens because of high noise;
analysis continued with the remaining 25 samples from 23
Table 1. Patient and tumor characteristics
Sample
ID
Sample
type
Site of
primary
tumor
Size of
primary
tumor (cm) Sex Age Disease course and comments
% Probes
aberrant
(42.3n or o1.75n)
MCPyV
detected?
MCCd1p Primary* Head/neck 1.1 F 79 Died of disease at 14 months 20 Y
MCCd1m Metastasis
of MCCd1p*
Head/neck 1.1 F 79 Died of disease at 14 months 17 Y
MCCd3p Primary* Buttock 6 M 45 Died of disease at 22 months; HIV+ 15 Y
MCCd3m Metastasis
of MCCd3p*
Buttock 6 M 45 Died of disease at 22 months; HIV+ 10 Y
MCCd5 Primary* Upper limb 5.2 M 63 No relapse at 14 months 3 N
MCCd6 Primary* Lower limb 2.3 M 50 No relapse at 436 months 6 Y
MCCd7 Node* Upper limb 0.6 F 76 No relapse at 436 months 4 Y
MCCd8 Primary* Head/neck 2.2 F 86 16 Y
MCCd9 Primary* Upper limb 1 F 69 3 Y
MCCd10 Primary* Flank 1.2 M 86 Patient on immunosuppressives 40 Y
MCCd11 Primary* Upper limb 1.7 F 85 Collision tumor with squamous-cell carcinoma 58 Y
MCCd12 Primary* Lower limb 1.3 M 85 Died disease free at 16 months; also had renal cancer 2 Y
MCCd13 Metastasis* Lower limb 2 M 80 Alive with disease at 6 months; NED at 30 months
(regression)
13 Y
MCCd14 Primary* Lower limb 2.5 M 47 Alive with disease at 5 months; still alive at 24 months 11 Y
MCCd15 Primary* Chest 0.5 M 73 No relapse at 5 months 6
MCCd16 Primary* Upper limb 1.6 M 72 No relapse at 10 months; patient has bladder cancer 63 N
MCCL1T Node Head/neck 0.6 F 63 Died of disease at 14 months 29 N
MCCL3T Node 0.2 M 68 No relapse at 436 months 35 N
MCCL4T Node Head/neck M 77 Died of disease at 40 months 24 N
MCCL5T Recurrence Head/neck F 72 Died of disease at 26 months 65 N
MCCL12T Recurrence Head/neck 3 M 61 Died of disease at 9 months 21 N
MCCL13T Node Head/neck 0.6 F 65 No relapse at 436 months 3 Y
MCCL16T Recurrence Head/neck 0.7 M 71 20 N
MCCL21T Node Lower limb M 82 Alive with disease at 33 months 10 Y
MCCLSm Primary Head/neck M 70 22 N
MCPyV; Merkel cell polyomavirus, presence detected by PCR; NED; No evidence of disease.
Asterisks (*) represent formalin-fixed paraffin embedded specimens; all other DNA was extracted from flash-frozen tumors. Times are reported as time since
diagnosis.
Data were not available for cells that remain empty.
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patients. Most specimens contained over 90% tumor cells,
and all specimens contained at least 70% MCC tumor cells.
The patients in this cohort were similar to prior reports
with regard to demographics (Table 1) as the average age at
diagnosis was 71 years, and 65% (15/23) were men (Allen
et al., 2005; Heath et al., 2008). Thirteen primary tumors, six
lymph node metastases, three distant metastases, and three
recurrences were studied. Primary tumor size information
was available for 12 of 13 primary tumors studied. In these
tumors, the diameter ranged between 0.5 and 6 cm, and the
median tumor size was 1.65 cm. Interestingly, we observed
no relationship between primary tumor size and extent of
copy number alteration (data not shown). The study included
a heterogeneous group of samples including primary,
recurrent, nodal metastasic, and distant metastatic tissues.
However, for the patients for which both a primary and
metastasis were profiled, the signatures were nearly identical
between the primary and metastasis, suggesting that hetero-
geneity of the sample types does not substantially affect
interpretation of the data.
Eight of the 25 specimens reported here had been
previously studied using classical CGH approaches (meta-
phase spreads). Specimens MCCL1T, MCCL3T, MCCL4T,
MCCL5T, MCCL12T, MCCL13T, MCCL16T, and MCCL21T
were previously reported as MCC1, MCC3, MCC4, MCC5,
MCC12, MCC13, MCC16, and MCC21, respectively (Van
Gele et al., 1998). An ‘‘L’’ is added to the original sample
names to avoid confusion with other samples in this study
labeled ‘‘d.’’ These samples were included in this study
because the array-CGH improves resolution of copy number
alteration allowing detection of previously unseen regions of
alteration.
Detection of the Merkel cell polyomavirus
Specimens were tested for the presence or absence of Merkel
cell polyomavirus (MCPyV or MCV) DNA by real-time PCR,
as described (Garneski et al., 2008b), and virus was detected
in tumors from 13 of 22 patients (59%; Table 1). We cannot
exclude the possible presence of a strain variant in samples
with no detectable MCPyV. Comparing virus positive MCC to
MCC with no detectable virus, there was a trend (not
significant) towards less aberration in virus positive tumors,
especially for regions of deletion (Supplementary Materials,
Figure S1).
Array-CGH detects focal changes in DNA copy number in MCC
tumors
Genome-wide array-CGH was performed on genomic DNA
extracted from both frozen and FFPE tissues. Although noise
tended to be greater with FFPE samples, sufficient signals
were detectable in most cases (Figure 1). For each sample, a
graphical plot and the associated raw numerical data are
included in Supplementary Materials (Figure S2).
Recurrent genomic changes across MCC tumors
Analysis of copy errors detection was used to identify regions
of copy number aberration for each MCC specimen (see
Materials and Methods section). To determine recurrent
regions of aberration, we combined the data from 23 MCC
specimens (only the primary was included for the two
patients with both primary and metastatic tissue analyzed).
For each probe, the percentage of MCC tumors that were
amplified or deleted was calculated (Figure 2). Magnitude of
aberration was not considered so long as the software
determined the change in copy number to be statistically
significant. A stringent cutoff was used to favor detection of
high amplitude events that are less likely to be technical
noises (see Materials and Methods section).
Chromosomes 1, 3q, 5p, and 6 were most frequently
increased in copy number whereas chromosomes 3p, 4, 5q,
7, 10, and 13 were most frequently lost. These global findings
concur with those previously published for MCC using
classical CGH (Harle et al., 1996; Van Gele et al., 1998,
2002; Popp et al., 2002; Larramendy et al., 2004). We also
performed recurrence analysis including only samples not
previously studied and found the genome-wide results to be
very similar (data not shown).
Low levels of genomic change were associated with improved
prognosis
To estimate the amount of overall genomic alteration per
sample, we called probes as aberrant if they had analysis of
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Figure 1. Genome-wide profile of a representative MCC tumor. Genome-wide overview of array-CGH data that graphically depicts changes in copy number
for sample MCCd10. On the x-axis (dotted line) data points are organized along the 22 autosomal chromosomes arranged from largest (on left) to smallest.
A dotted line is shown at the level of 2n (normal) relative DNA amount and the y-axis depicts relative copy number on a logarithmic scale. Light gray dots
represent individual data points, and the dark gray line represents the line of moving average fit (see Materials and Methods section). DNA for this tumor was
extracted from a paraffin-embedded specimen, and noise is characteristic. Arrow points to focal amplification on chromosome 1 containing L-Myc. Plots in this
format are included in Supplementary Materials (Figure S2) for all specimens.
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copy errors analyzed log-ratio values greater than 0.2 or less
than 0.2 (42.3n and o1.75n relative copy number,
respectively). We then calculated the percentage of probes
that were aberrant for each tumor. It must be noted that the
simple calculation of log2 ratio to actual copy number does
not take into account the small amount of stromal contam-
ination or heterogeneity. However, we feel this approxima-
tion is useful as it aids interpretation of our findings.
We observed a wide range of genomic variation between
MCC tumors. Three tumors had very high levels of alteration
with450% probes aberrant, whereas five tumors had almost
no detectable copy number alteration with o5% probes
aberrant. Copy number transitions were also determined, and
the number of copy number transitions was highly correlated
with percentage aberration for any given tumor (data not
shown). Percent aberration and copy number transition are
different metrics of overall genome rearrangement. The
former estimates the percentage of the overall genome
with an aberrant copy number, and the latter gives the
average number of chromosomal rearrangements or breaks
in a given tumor. The percentage aberration metric was
chosen for analysis because a copy number transition
analysis scores a narrow region of alteration the same as a
wide region and may underrepresent the amount of genomic
change.
Disease-specific survival information was available for 17
patients. To investigate whether the percentage of aberrant
probes for each tumor was associated with cause-specific
survival, tumors were assigned to one of two groups: less
aberration (fewer than 15% probes aberrant) or more
aberration (15% or more probes aberrant). As shown in
Figure 3, less aberration was associated with significantly
improved disease-specific survival (P¼0.04). Less aberration
was associated with excellent cause-specific survival
whereas outcomes in the more aberration group were mixed.
Previous studies have also reported that low aberration in
MCC tumors is associated with improved survival (Van Gele
et al., 1998; Larramendy et al., 2004); however, this study is
the first such association to reach statistical significance.
Three interesting narrow regions of amplification and deletion
Several of the regions of recurrent genomic aberration were
especially interesting because they were altered in a
substantial portion (425%) of MCC tumors, were focal
enough to contain fewer than 100 annotated genes, and
contained biologically plausible known cancer-related genes.
Graphical images of these three regions are shown in Figure
4, and accompanying information is in Table 2.
Previous studies have reported that RB1, a well-character-
ized tumor suppressor, is lost in a subset of MCC tumors (Van
Gele et al., 1998). Of 23, 6 tumors in our study had losses of
chromosome 13q14-13q21 (Figure 4a).
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Figure 2. Recurrent changes in relative DNA copy number in 23 Merkel cell carcinomas. The 22 autosomal chromosomes are arranged horizontally along
the x-axis, from largest to smallest, with ‘‘p’’ arms to the left. At each genomic location, the percentage of tumors that have an aberration is shown on the
y-axis. Significant gains and losses in relative copy number were determined using ACE detection (see Materials and Methods section). (a) Recurrent gains
across the genome. The arrow points to the 1p34 amplification detailed in Figure 4. (b) Recurrent losses across the genome. Arrows represent the 5q and 13q
deletions detailed in Figure 4. A similar figure in which Merkel cell polyomavirus positive and negative tumors are shown separately is available in
Supplementary Materials (Figure S1).
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Figure 3. Extent of genomic aberration is associated with disease-specific
survival. Survival data was available for 17 patients. This Kaplan–Meier
analysis compares disease-specific survival of patients whose tumors
displayed less genomic aberration (solid line,o15% of CGH probes aberrant)
and those whose tumors displayed more genomic aberration (dotted line,
15% or more probes aberrant). Aberration was defined as a probe being
42.3n or o1.75n. Patients with less aberration displayed significantly
improved survival, P¼0.04 by log-rank test.
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Figure 4. Three narrow regions of recurrent amplification or deletion. Chromosome arms 13q (a), 5q (b), and 1p (c) are shown. These regions were
selected because of their high recurrence (425% of MCCs altered) and focal nature. Colored lines represent individual tumor samples with copy number
alteration in the region, and gray lines represent the remaining samples. For further details on these regions see Table 2. (d) Three samples with the highest
relative copy number of the 1p34 region are shown in detail. The colored lines are moving average fit lines redrawn from (c), and the gray dots represent
individual data points. The probe targeting L-Myc is shown with a blue asterisk. Cent¼ centromere, pTer¼ p-terminal, qTer¼ q-terminal. Note y-axis scale
difference between (a) and (b) versus (c).
Table 2. Characteristics of minimum common regions shown in Figure 4
Location of recurrent
copy number alteration
Chromosome
13q14.11-13q21.33
Chromosome
5q12.3-5q21.1
Chromosome
1p34.3-1p34.2
Type of alteration Deletion Deletion Amplification
Approximate size (kb) 30,700 34,700 3,400
Tumors with copy number
alteration
MCCd1, MCCd16, MCCL1T,
MCCL3T, MCCL5T, MCCL13T
MCCd1, MCCd16, MCCL1T,
MCCL5T, MCCL12T, MCCLSm
MCCd1, MCCd8, MCCd10, MCCd11, MCCd16,
MCCL3T, MCCL12T, MCCL16T, MCCLSm
Number of named genes in region 67 94 29
Genes of interest RB1, TPT1, RFP2, DLEU1,
DLEU2, DLEU7
XRCC4, RASA1 MYCL1, MYCBP, HEYL
Functional RNAs in region miR-16-1, miR-15a,
miR-621,
ACA31
miR-9-2, miR-583, HBI-115, U109 miR-30e, miR-30c, ACA55
A list of all annotated genes in each region is included in Table S1.
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A region of recurrent deletion was located at chromosome
5q12-21 (Figure 4b). This region was lost in 6 of 23 tumors.
A previous study found that this region is also deleted in
71% of BRCA1-mutant breast cancers (n¼42), which
suggests it may contain a tumor suppressor (Johannsdottir
et al., 2006).
We found a previously unreported recurrent amplification
at 1p34 (Figure 4c). The region is amplified in 9 of 23 tumors;
two specimens have especially focal amplifications and an
average relative copy number of 410 n. The 1p34 region is
gene rich and contains 29 annotated genes including L-Myc,
a close relative of the protooncogene c-Myc. No relationship
was observed between these three narrow regions of
aberration and the presence of MCPyV DNA.
L-Myc is expressed in MCC tumors
We chose the 1p34 amplification for further analysis because
of the focal, high-magnitude copy number increase in a
subset of MCC tumors. Among the 29 genes in this region, we
focused on the L-Myc gene because it is at the center of the
peak of the focal amplification (Figure 4d). Furthermore,
L-Myc is the most biologically plausible candidate oncogene
in this region, and it has been implicated as potentially
relevant in small cell lung cancer (SCLC), a closely related
neuroendocrine tumor (Kim et al., 2006).
Using quantitative PCR, we confirmed the DNA copy
number of the L-Myc gene in four MCC specimens for which
additional FFPE tumor was available (Figure 5a). We further
used reverse-transcription PCR to test for RNA expression of
L-Myc. In a specimen of UV-exposed normal adult skin used
as a control, b-actin was expressed but L-Myc was
undetectable. In contrast, all four MCC tumors expressed
both b-actin and L-Myc (Figure 5b). Furthermore, the three
tumors with gene amplification expressed L-Myc RNA in
higher levels proportional to their DNA copy number
increase.
DISCUSSION
We utilized array-based CGH to generate the most compre-
hensive overview of genomic aberration in MCC. Among our
25 specimens, the general pattern of recurrence agreed with
previous studies with chromosomes 1, 5, 6, and 10 most
frequently altered. For the 17 specimens with associated
complete survival information, we found a statistically
significant association between the amount of genomic
aberration and survival. Less aberration was associated with
better outcome. This suggests that genomic instability may be
involved in the pathogenesis of MCC. There were too few
samples, however, to determine prognostic information for
individual aberrations. Of the recurrent alterations detected
in this study, the most significant is the high amplitude, focal
amplification of 1p34. This centers on L-Myc, which is a
highly plausible oncogene implicated in a closely related
neuroendocrine cancer. L-Myc RNA expression was in-
creased in proportion to DNA amplification. We anticipate
that our complete CGH results, made available in Supple-
mentary Materials, will help inform future studies of
neuroendocrine tumors.
Eight specimens in our study had been previously studied
using CGH on metaphase spreads (Van Gele et al., 1998).
The array-CGH technology detected several focal regions of
copy number change that were previously missed. For
example, in sample MCCL3T, array-CGH newly identified a
gain on the terminal of 14q32-14qter that contains AKT1, a
well-known gene with antiapoptotic functions. In sample
MCCL1T, we found a previously unreported narrow deletion
on chromosome 4q21-4q22 that contains a protein phospha-
tase, PTPN13, that acts as a tumor suppressor (Spanos et al.,
2008). Further, we found that sample MCCL12T had a
narrow high-magnitude amplification on chromosome
11p13. This region contains only one full gene, CD44, which
is a cell surface protein involved in hyaluronic acid biology
and cell migration/metastasis (Gotte and Yip, 2006; Sackstein
et al., 2008). These interesting findings highlight the utility of
the detailed data derived from the present array-CGH
platform.
The 13q14-13q21 region of recurrent deletion contains
the RB1 gene. Of the six MCC tumors that had deletions in
this region, four were previously reported to have this
deletion and indeed had lost expression of RB1 protein
(Van Gele et al., 1998). Interestingly, the miRNAs
miR-16-1 and miR-15a are also located in this portion of
chromosome 13. These miRNAs are postulated to act as
tumor suppressors by posttranscriptionally downregulating
β
Figure 5. L-Myc DNA amplification and RNA expression in selected MCC
tumors. Four tumors with ample remaining materials were chosen for
additional analysis. Three of these tumors (MCCd8, MCCd10, MCCd11) had
amplification of the L-Myc locus by aCGH, and one tumor (MCCd9) had
normal, 2n copy number at the L-Myc locus (Figure 4c). (a) Quantitative PCR
confirmation of L-Myc DNA copy number amplification. White bars represent
copy number determined by array-CGH, and black bars represent copy
number as determined by real-time PCR. NS¼normal skin (not predicted to
have amplification of L-Myc). (b) L-Myc RNA is expressed in proportion to
DNA amplification. L-Myc expression was investigated using reverse-
transcription PCR. Top row: L-Myc is expressed in all four studied tumors but
not in normal skin. The positive control for L-Myc PCR detection (pos) was an
L-Myc expression construct. Middle row: b-Actin served as a positive control.
Bottom row: As a negative control, the same experiments were performed
without reverse-transcriptase (RT). Three reactions were run for all conditions,
and the gels shown are representative.
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BCL-2 (Cimmino et al., 2005). Thus the loss of these miRNAs
may be linked to BCL-2 upregulation. This is relevant
because BCL-2 protein levels are commonly elevated in
MCC tumors (Kennedy et al., 1996; Plettenberg et al., 1996),
and high BCL-2 levels have been shown to be functionally
important in an MCC xenograft model (Schlagbauer-Wadl
et al., 2000).
A copy number increase at chromosome 1p34 occurred in
39% of tumors. This previously unreported finding, combined
with our RNA expression data, raises the possibility of a role
for L-Myc in MCC tumorigenesis. L-Myc is a transcription
factor that is closely related to the well-characterized
protooncogene c-Myc and its homolog n-Myc (Nau et al.,
1985). The Myc genes are basic helix–loop–helix transcrip-
tional regulators. Like c-Myc and n-Myc, when L-Myc is
overexpressed it is able to synergize with Ras to transform
fibroblasts in culture. In the cell types tested, L-Myc does so
with a reduced efficiency (1–10% of the efficiency of c-Myc);
however, lines transformed by L-Myc are identical in
phenotype and growth rate to those transformed by c-Myc
overexpression (Birrer et al., 1988).
Unlike the well-characterized c-Myc and n-Myc, the
functional role of L-Myc in human cancer is less well
defined. L-Myc was initially discovered in SCLC where it is
increased in copy number 10- to 20-fold (Nau et al., 1985).
SCLC is a neuroendocrine tumor that shares nearly identical
histology with MCC. In several SCLC cell lines with L-Myc
amplifications, a reduction of L-Myc expression inhibited cell
line growth in a dose-dependent manner (Dosaka-Akita et al.,
1995). A recent array-based approach investigated gene
amplification and expression profiles in 24 SCLC cell lines
(Kim et al., 2006). Of 24, 13 cell lines carried amplifications
of c-Myc, n-Myc, or L-Myc. Interestingly, no cell line carried
a DNA amplification of more than one Myc gene, suggesting
amplification of the various Myc genes may be functionally
reciprocal. However, expression analysis showed that the
downstream effects of c-Myc, n-Myc, and L-Myc amplifica-
tion differed, so the exact mechanism of L-Myc oncogenesis
remains unclear.
A newly discovered polyomavirus, MCPyV, was recently
reported to be associated with MCC tumors (Feng et al.,
2008). This virus remains to be functionally characterized but
may plausibly contribute to a subset of MCCs because it is
predicted to encode two oncogenic proteins (‘‘T antigens’’;
Garneski et al., 2008a). We tested our samples for the
presence or absence of MCPyV DNA (Table 1) and found that
samples with detectable viral DNA had fewer deletions than
those without (Supplementary Materials, Figure S1). A
notable exception is chromosome arm 19q, deleted in the
majority of virus positive MCC but rarely deleted in virus
negative MCC. The significance of these findings remains
unclear, and a more complete analysis of the potential
interplay between MCPyV and genomic changes is beyond
the scope of this report.
The present array-CGH study of 25 MCC tumors provides
insight into genetic aberrations in this poorly understood
disease. This highresolution dataset is made available to the
public to help advance studies of this lethal cancer.
Furthermore, these findings suggest an exciting new lead for
further study; L-Myc amplification is possibly involved in the
pathogenesis of MCC. Future studies are needed to char-
acterize a possible functional role of Myc family members in
MCC.
MATERIALS AND METHODS
Patients and tumor samples
In adherence with the Declaration of Helsinki Principles and
keeping with National Institutes of Health guidelines for the
protection of human subjects, institutional review board approval
was obtained from Dana-Farber/Harvard/Partners; patient consent
was not required for the use of discarded human tissues. The MCC
tumor samples were FFPE archival specimens or flash-frozen surgical
tissue. FFPE tumor sections were obtained from Dana-Farber/
Brigham and Women’s Cancer Center Pathology or from Cohen
Dermatopathology. For two patients, samples of both the primary
and metastasis were available (MCCd1p, MCCd1m, MCCd3p, and
MCCd3m). Tumor samples with a name containing the letter ‘‘L’’
were provided as DNA extracted from flash-frozen Australian MCC
tumor specimens that are previously described (Leonard et al.,
1996). MCC diagnoses were made by a dermatopathologist and
confirmed with immunohistochemistry and/or with lung imaging to
rule out a metastasis originating from a SCLC primary tumor.
DNA and RNA extraction from FFPE tissues
For DNA extraction, 10 mm sections were cut from FFPE blocks
containing at least 70% tumor cells as determined by microscopic
examination of adjacent sections. Paraffin was removed by
sequential xylene and ethanol washes, and the formalin was
removed by a phosphate-buffered saline wash (pH 7.2). DNA was
purified using a DNeasy Tissue Mini kit (Qiagen, Valencia, CA) and
the integrity confirmed by visualization on a 1% agarose gel. RNA
was extracted from 5mm sections of the same block using the
RNeasy FFPE kit (Qiagen).
Array-CGH
A total of 15 mg of genomic DNA were digested with AluI and RsaI
(New England Biolabs, Ipswich, MA) and purified using the
QIAquick PCR Purification kit (Qiagen). DNA was eluted in water
and diluted to 100 ng ml1. DNA was random-prime labeled as
described (Aguirre et al., 2004) and hybridized to human 60-mer
oligonucleotide microarrays (Agilent, Santa Clara, CA). A single
batch of human, male, pooled lymphocyte DNA was used for the
reference DNA for all samples (Promega, Madison, WI). Please see
the complete description of this hybridization protocol for further
details (Protopopov et al., 2008). Samples MCCL4T, MCCL12T,
MCCL13T, MCCL21T, and MCCLSm were run on G4410B chip and
the remainder were run on the G4410A chip. The microarrays
contain over 40,000 coding and noncoding sequences, and provide
43 kb overall median resolution, which improves to a resolution of
24 kb in gene rich regions. The fluorescence ratios for samples
MCCd1p, MCCd3p-MCCd16, MCCL1T, MCCL3T, MCCL5T, and
MCCL16T were calculated using the average of two paired (dye
swap) arrays. The fluorescence ratios for tumor samples MCCd1m,
MCCL4T, MCCL12T, MCCL13T, MCCL21T, and MCCLSm were
calculated using a single dye array; this was feasible because of
higher DNA quality from the frozen tissues.
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Detection of Merkel cell polyomavirus
Tumor specimens were tested for the presence of MCPyV DNA by
real-time PCR as described (Garneski et al., 2008b). One specimen
was not available for testing because of insufficient sample volume.
The viral status of 14 of these samples were previously reported
(Garneski et al., 2008b).
Quantitative PCR
Confirmation of L-Myc copy number was performed by real-time
quantitative PCR. Primers were designed to amplify L-Myc and
control genomic DNA sequences. The control sequence was
selected within a region of euploid copy number on chromosome
2 (near the TPO gene). A total of 2.5 ng of DNA were combined with
primers and 2 SYBR green PCR mastermix (Applied Biosystems,
Foster City, CA), denatured at 95 1C for 10minutes, and then run for
40 cycles of 95 1C for 15 seconds followed by 1minute of annealing
at 60 1C. Fluorescence was detected using an Applied Biosystems
7900 HT sequence detection system, and relative quantities were
determined using the comparative Ct (D–D Ct) method as described
by the manufacturer. DNA from FFPE sun exposed, disease free,
normal human skin was used as a control for copy number, and
water served as a negative control. Copy number was compared to
the moving average fit values for 1p34 (Figure 4c). All wells were run
in triplicate, and the experiment was repeated twice. Several
genomic sequences located on chromosomes 1, 3, 10, and 14 were
also studied to confirm validity of CGH results, and all were
consistent with CGH findings (data not shown). Primer sequences
are as follows: control (TPO) forward AACTTCCTGAGCCAACAAGC
and reverse CACACATTACCCGTTGGATG (expected product length
127 bp), L-Myc forward CAGTGAGCTTTCTTGGTCCT and reverse
TGGCATCTTAGACCTCCACA (expected product length 105 bp).
Reverse-transcription PCR
The high capacity cDNA reverse-transcription kit (Applied Biosys-
tems) was used with random primers to reverse transcribe 0.5mg of
total RNA. Primers were designed to b-actin (PCR control) and
L-Myc. Forward and reverse primers were designed to span exons so
as to only amplify cDNA. In addition, the same experiments were
repeated without reverse transcriptase as a negative control. cDNA
was amplified with 38 cycles of PCR (95 1C for 15 seconds then
60 1C for 1minute); the product was visualized on an 8% acrylamide
Tris borate EDTA gel stained with ethidium bromide. One picogram
of a plasmid containing full length L-Myc cDNA was used as the
positive control. We were unable to assay levels of L-Myc protein
because no adequate antibody is commercially available. Primer
sequences are as follows: control (b-actin) forward AGAGCTAC
GAGCTGCCTGAC and reverse AAGGTAGTTTCGTGGATGCC (ex-
pected product length 129 bp), L-Myc forward AGCGACTCGGAGA
ATGAAGA and reverse CAGCTTTCTGGAGGAAAACG (expected
product length 180 bp).
Statistical analysis
Array data was log transformed and mode centered. The CGH-
Explorer program (version 3.1; Lingjaerde et al., 2005) was used
to visualize and analyze the CGH data. Genome-wide profile
images displaying the raw data for each sample were plotted, and a
‘‘moving average fit’’ line was applied to each image (neighborhood
size¼ 29). Images for each sample are included in Supplementary
Materials (Figure S2). Views of the minimum common regions
for Figure 4 were also generated using moving average fit;
individual data points were not displayed for (a), (b), and (c), and
the neighborhood size was increased to 39 to better enable
visualization of multiple samples on the same graph. Statistically
significant copy number alterations were identified by applying
the analysis of copy errors detection algorithm (Lingjaerde et al.,
2005), which is a validated algorithm used to determine regions
of loss and gain (Meza-Zepeda et al., 2006). Data from the 22
autosomal chromosomes were analyzed. Sex chromosomes
were excluded because of gender differences between patients.
The stringent cutoff of the false discovery rate was set at 0.003,
indicating three probes per 1,000 were falsely called aberrant.
The terms ‘‘copy number gain’’ and ‘‘amplification’’ are used
synonymously in this paper to denote a DNA gain. Raw array
data and complete analysis results are included in Supplementary
Materials and will be posted at the Progenetix online resource
(www.progenetix.net) and at the NCI and NCBI’s Raw array data and
complete analysis results are included in Supplementary Materials
and will be posted at the Progenetix online resource (www.
progenetix.net) and at the NCI and NCBI’s GEO Database (http://
www.ncbi.nlm.nih.gov/geo/). Annotated genes within the three
narrow regions of recurrent aberration (Figure 4 and Table 2) were
identified using the Santa Cruz Genome Browser. Kaplan–Meier
curves were generated using GraphPad Prism, version 5 (GraphPad
Software, San Diego, CA).
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SUPPLEMENTARY MATERIAL
Table S1. Full list of named genes from minimum common regions in Table 2.
Figure S1. Recurrent changes in relative DNA copy number in Merkel cell
carcinomas with and without detectable Merkel cell polyomavirus (MCPyV).
Figure S2. Genome-wide profiles of Merkel cell carcinoma tumors studied.
Array CGH Data File. Log base 2 transformed and Analysis of Copy Error
(ACE) analyzed CGH data (txt file).
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